Heartland Express, Inc. Declares Regular Quarterly Dividend NORTH LIBERTY, Iowa, March 13, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on April 3, 2026, to shareholders of record at the close of business on March 24, 2026. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's ninety-first consecutive quarterly cash dividend. Wit...
NOVAGOLD & Paulson Award Engineering Contracts to WSP, Worley, and Hatch for Key Infrastructure and Unit Operations in Bankable Feasibility Study VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) and Donlin Gold Holdings (DGH), 100% wholly-owned by Paulson Advisers LLC (“Paulson”) and its affiliates, are pleased to announce the awarding of specialized contracts to three top-tier engineering firms — WSP USA, Inc. (“WSP”), Worley Alaska Inc. (“Worley”), and Hatch Ltd. (“Hatch”) — to advance key infr...
Sunrise Realty Trust, Inc. Announces Financial Results for the Fourth Quarter and Full Year 2025 Fourth quarter 2025 GAAP net income of $1.6 million or $0.12 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.27 per basic weighted average common share Full year 2025 GAAP net income of $12.1 million or $0.93 per basic weighted average common share and Distributable Earnings of $15.2 million or $1.19 per basic weighted average common share Board of Directors declares a first quarter 2026 dividend of $0.30 per common share WEST PALM BEACH, Fla., Marc...
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosingBiogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world CA...
Sunrise Realty Trust Expands Revolving Credit Facility to $165 Million with Addition of Customers Bank WEST PALM BEACH, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (“SUNS” or the “Company”) (Nasdaq: SUNS), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced the expansion of its senior secured revolving credit facility (the “Credit Facility”) with the addition of Customers Bank. Customers Bank has committed $25 million to the facility, bringing total committed capital to $165 million. The Credit Facility, originally established wit...
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.